title: Use of celecoxib correlates with increased relative risk of acute pancreatitis: a case-control study in Taiwan.
abstract: OBJECTIVE
  This study evaluated whether there is an association between the use of celecoxib and acute pancreatitis in Taiwan.
  
  
  METHODS
  We conducted a case-control study using the database of the Taiwan National Health Insurance Program. The participants comprised 5,095 subjects, aged 20-84 years, with a first admission episode of acute pancreatitis from 2000 to 2011 as the cases and 20,380 randomly selected sex-matched and age-matched subjects without acute pancreatitis as the controls. The absence of celecoxib prescription was defined as "never used." Current use of celecoxib was defined as subjects who had received at least one prescription for celecoxib within 3 days before diagnosis with acute pancreatitis. A multivariate unconditional logistic regression model was used to calculate the odds ratio (OR) and 95% confidence interval (CI) for acute pancreatitis associated with the use of celecoxib.
  
  
  RESULTS
  Compared with subjects who never used celecoxib, the adjusted OR of acute pancreatitis was 5.62 in subjects with current use of celecoxib (95% CI=3.33-9.46).
  
  
  CONCLUSIONS
  The current use of celecoxib is associated with an increased risk of acute pancreatitis.
authors: Department of Emergency Medicine, Nantou Hospital, Nantou, Taiwan.
authors: Shih-Chang
authors: SC
authors: Hung
authors: Department of Pharmacy, Erlin Christian Hospital, Changhua, Taiwan.
authors: Shih-Rong
authors: SR
authors: Hung
authors: College of Medicine, China Medical University, Taichung, Taiwan.|Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.
authors: Cheng-Li
authors: CL
authors: Lin
authors: College of Medicine, China Medical University, Taichung, Taiwan.|Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.
authors: Shih-Wei
authors: SW
authors: Lai
authors: Division of Gastroenterology, Department of Internal Medicine, Nantou Hospital, Nantou, Taiwan.
authors: Hung-Chang
authors: HC
authors: Hung
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019973:Alcohol-Related Disorders / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology; D016022:Case-Control Studies; D000068579:Celecoxib / Q000627:therapeutic use*; D002769:Cholelithiasis / Q000453:epidemiology; D015897:Comorbidity; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D016208:Databases, Factual; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010195:Pancreatitis / Q000453:epidemiology*; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology; D051436:Renal Insufficiency, Chronic / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan / Q000453:epidemiology; D055815:Young Adult
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D000068579:Celecoxib